The provocative results demonstrating the anticancer effects of MET in all breast cancer subtypes, including potential in BRCA1 carriers in population studies, preclinical and retrospective clinical trials have lead to initiation of several phase I-III clinical trials evaluating MET for both for treatment and prevention in early stage to metastatic, cytotoxic therapy-resistant models of breast cancer and in adjuvant therapies. The gene discussed is BRCA1; the disease is breast cancer.